Comparison
46 Xx True Hermaphroditism Sry Positive Cn322638 vs 4 Hydroxyphenylpyruvic Aciduria C1848678
Clinical comparison between 46 XX True Hermaphroditism Sry Positive CN322638 and 4 Hydroxyphenylpyruvic Aciduria for differential diagnosis and treatment planning.
46 Xx True Hermaphroditism Sry Positive Cn322638
A rare DSD where an individual has both ovarian and testicular tissue. Occurs in 46,XX persons, often with SRY gene present. Management includes hormone therapy and individualized surgical options.
4 Hydroxyphenylpyruvic Aciduria C1848678
A metabolic disorder involving difficulty processing tyrosine, an amino acid. Can affect development and growth. Treatment focuses on dietary management and supportive care.
6 comparison axes
Onset
46 Xx True Hermaphroditism Sry Positive Cn322638
0-0
4 Hydroxyphenylpyruvic Aciduria C1848678
0-5
Onset patterns differ
Severity
46 Xx True Hermaphroditism Sry Positive Cn322638
severe
4 Hydroxyphenylpyruvic Aciduria C1848678
moderate
Different severity levels
Chronic
46 Xx True Hermaphroditism Sry Positive Cn322638
Chronic
4 Hydroxyphenylpyruvic Aciduria C1848678
Chronic
Differing course
Communicable
46 Xx True Hermaphroditism Sry Positive Cn322638
No
4 Hydroxyphenylpyruvic Aciduria C1848678
No
Different transmission
Body System
46 Xx True Hermaphroditism Sry Positive Cn322638
reproductive
4 Hydroxyphenylpyruvic Aciduria C1848678
metabolic
Same/different system
Category
46 Xx True Hermaphroditism Sry Positive Cn322638
genetic
4 Hydroxyphenylpyruvic Aciduria C1848678
metabolic
Different category
Bottom line
46-xx-true-hermaphroditism-sry-positive-CN322638 and 4-hydroxyphenylpyruvic-aciduria-C1848678 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx True Hermaphroditism Sry Positive Cn322638 | 4 Hydroxyphenylpyruvic Aciduria C1848678 | Discriminating power |
|---|---|---|---|
| Gonadal development | Both ovarian and testicular tissue may be present from birth. | No primary gonadal differentiation disorder is described. | High |
| Metabolic features | Tyrosine-processing abnormality is not part of the supplied description. | Difficulty processing tyrosine may affect growth or development. | High |
| Onset pattern | Coded as congenital, present at birth. | Onset is described from birth through early childhood. | Moderate |
When to favor each condition
Choose 46 Xx True Hermaphroditism Sry Positive Cn322638 when
Mixed gonadal tissue is identified
Ovarian plus testicular tissue defines the supplied DSD concept.
High
46,XX karyotype with SRY detected
This genetic pattern matches the named left condition.
High
Hormone or surgical planning for DSD
Management is individualized endocrine and surgical care.
Moderate
Choose 4 Hydroxyphenylpyruvic Aciduria C1848678 when
Tyrosine metabolites are abnormal
The finding concerns impaired tyrosine processing, pending clinician review.
Moderate
Growth or development concerns without DSD
Supplied effects involve development and growth rather than gonads.
Moderate
Dietary metabolic management is being considered
Described care centers on diet and supportive treatment.
Moderate
How key tests differ
| Test | 46 Xx True Hermaphroditism Sry Positive Cn322638 | 4 Hydroxyphenylpyruvic Aciduria C1848678 | Interpretation |
|---|---|---|---|
| Karyotype and SRY testing | 46,XX, often with SRY present. | Not described as defining this metabolic finding. | Supports the DSD when correlated with gonadal findings; clinician confirmation is required. |
| Gonadal histology or imaging | Evidence of both ovarian and testicular tissue. | No characteristic gonadal abnormality is supplied. | Tissue findings distinguish the DSD; imaging alone may be insufficient. |
| Tyrosine metabolite assessment | No expected pattern is established here. | Abnormal tyrosine-related metabolites may be found; no cutoff is supplied. | An abnormal result suggests a metabolic problem but does not alone establish the diagnosis. |
Prognosis comparison
46 Xx True Hermaphroditism Sry Positive Cn322638
- Outcome
- Chronic congenital condition; long-term outcome is not quantified here.
- Factors
- Gonadal findings, hormone needs, and surgical decisions may influence course.
4 Hydroxyphenylpyruvic Aciduria C1848678
- Outcome
- Chronic metabolic condition of moderate coded severity; outcome data are not supplied.
- Factors
- Degree of tyrosine-processing difficulty, growth, development, and dietary adherence may matter.
Time frame: Lifelong follow-up is generally relevant; exact milestones are not established.
Specialist monitoring and individualized treatment are central; mortality and exact prognosis are not provided.
Complications comparison
| Complication | Presentation |
|---|---|
| Hormonal effects | Hormone therapy may be needed; exact effects vary. Primary hormonal disorder is not described. Endocrine needs should be individualized and are not fully specified. |
| Growth and development | Developmental impact is not established by the source. Growth and development may be affected. Severity and specific deficits are not quantified here. |
| Treatment burden | May involve hormones and individualized surgery. May involve dietary management and supportive care. Neither doses nor operative indications are established in the source. |
Patient education highlights
- HighDistinct conditions
One is a reproductive DSD and the other a tyrosine-related metabolic finding; neither is communicable.
- HighResult versus diagnosis
Genetic or metabolite abnormalities need specialist interpretation and do not automatically confirm the full condition.
- MediumCare planning
DSD care may include hormones and surgery; metabolic care emphasizes diet and support. Decisions are individualized.